HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients

HLS-SX-682 在 MDS 患者中的 1 期开放标签剂量递增和扩展研究

基本信息

  • 批准号:
    9789451
  • 负责人:
  • 金额:
    $ 142.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-01 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

This SBIR Fast-Track proposal meets the objectives of NHLBI Small Business Topic of Special Interest for Fiscal Year 2017 Code HLS17-04. Myelodysplastic syndromes (MDS) are genetically and morphologically diverse hematopoietic neoplasms that arise from a small pool of mutant clones within hematopoietic stem and progenitor compartments. Only three drugs have received regulatory approval specifically for MDS treatment, all with suboptimal response rates of <50% and of limited durability, typically 1-2 years. Once these agents are no longer effective, there is no standard of care established for second-line treatment (i.e., in the relapsed/refractory setting). Furthermore, prognosis after hypomethylating agent failure is dismal, with median survival estimated at <6 months for higher-risk patients, and <18 months for lower-risk patients. Clearly there is a significant unmet need for a new MDS treatment that both (a) eradicates preleukemic stem cells and leads to long-term remission and normalization of cytopenias, and (b) achieves this goal without the heavy cost of side effects, particularly in lower-risk MDS. Stem cells and early progenitors from MDS patients consistently overexpressed the chemokine CXCL8 (IL-8) and its receptor, CXCR2. Inhibition of CXCR2 selectively arrested the growth of stem cells from MDS patients but not healthy controls, demonstrating preclinical therapeutic proof-of-principle and validating CXCR2 as a therapeutic target in MDS. Additionally, myeloid-derived suppressor cells (MDSCs) are markedly increased in the bone marrow of MDS patients where they induce myelodysplasia and impair immune surveillance and clearance of mutant clones. CXCR2 and CXCR1 are pivotal in MDSC recruitment. Dual CXCR1 and CXCR2 (CXCR1/2) inhibition is therefore a novel therapeutic strategy to treat MDS with a “one- two punch” to (i) the mutant MDS cells directly and (ii) the MDSC-driven immunosuppressive marrow microenvironment. Developed by Syntrix in a decade's long discovery effort supported by NHLBI (IND open for melanoma 4/16), SX-682 is a new-in-class oral, small-molecule, immuno-oncology (IO) therapy directed at disrupting CXCR1/2 signaling. We hypothesize that in MDS, SX-682 will lead to long-term remissions and normalization of cytopenias, but with only a mild side-effect effect profile compared to other therapies. If successful, SX-682 would revolutionize the existing treatment landscape in MDS. Through execution of the Specific Aims, we will advance SX-682 through a Phase 1, open label dose-escalation and expansion trial to evaluate SX-682 in MDS patients who had progression or were intolerant to prior therapy. The SX-682 MDS IND 131,876 was opened on September 1, 2017, and enrollment for this trial may begin.
此 SBIR 快速通道提案符合 NHLBI 小企业特别感兴趣主题的目标 2017 财年代码 HLS17-04。骨髓增生异常综合征 (MDS) 具有遗传和形态学特征 由造血干细胞内的一小部分突变克隆产生的多种造血肿瘤 祖室。只有三种专门用于MDS治疗的药物获得了监管部门的批准, 所有这些的响应率都低于 50%,且持续时间有限,通常为 1-2 年。一旦这些代理 不再有效,没有为二线治疗制定护理标准(即在 复发/难治性情况)。此外,低甲基化药物失败后的预后很差,中位 高风险患者的生存估计为<6个月,低风险患者的生存估计为<18个月。显然有 对于一种新的 MDS 治疗方法来说,这是一个未得到满足的重大需求,该治疗方法既可以 (a) 根除白血病前期干细胞,又可以导致 血细胞减少症的长期缓解和正常化,并且(b)无需付出高昂的代价即可实现这一目标 副作用,特别是在低风险 MDS 中。 MDS 患者的干细胞和早期祖细胞始终过度表达趋化因子 CXCL8 (IL-8) 及其受体 CXCR2。抑制 CXCR2 可选择性抑制 MDS 干细胞的生长 患者而非健康对照,展示临床前治疗原理验证并验证 CXCR2 作为 MDS 的治疗靶点。此外,骨髓源性抑制细胞 (MDSC) 显着 MDS 患者的骨髓增加,导致骨髓增生异常并损害免疫系统 突变克隆的监视和清除。 CXCR2 和 CXCR1 在 MDSC 招募中至关重要。双重的 因此,CXCR1 和 CXCR2 (CXCR1/2) 抑制是一种新的治疗策略,以“单- “两拳”直接作用于(i)突变型 MDS 细胞和(ii)MDSC 驱动的免疫抑制骨髓 微环境。 由 Syntrix 在 NHLBI 支持下经过十年的长期发现努力而开发(针对黑色素瘤的 IND 开放) 4/16),SX-682 是一种新型口服小分子免疫肿瘤 (IO) 疗法,旨在破坏 CXCR1/2 信号传导。我们假设在 MDS 中,SX-682 将导致长期缓解和正常化 血细胞减少症,但与其他疗法相比只有轻微的副作用。如果成功,SX-682 将彻底改变 MDS 现有的治疗格局。通过具体目标的执行,我们将 通过第一阶段、开放标签剂量递增和扩展试验推进 SX-682,以评估 SX-682 病情进展或对先前治疗不耐受的 MDS 患者。 SX-682 MDS IND 131,876 是 于 2017 年 9 月 1 日开放,该试验的注册可能会开始。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STUART J KAHN其他文献

STUART J KAHN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STUART J KAHN', 18)}}的其他基金

A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
  • 批准号:
    10372803
  • 财政年份:
    2019
  • 资助金额:
    $ 142.44万
  • 项目类别:
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
  • 批准号:
    10029002
  • 财政年份:
    2019
  • 资助金额:
    $ 142.44万
  • 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
  • 批准号:
    9348033
  • 财政年份:
    2017
  • 资助金额:
    $ 142.44万
  • 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
  • 批准号:
    10189528
  • 财政年份:
    2017
  • 资助金额:
    $ 142.44万
  • 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
  • 批准号:
    9755385
  • 财政年份:
    2017
  • 资助金额:
    $ 142.44万
  • 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
  • 批准号:
    8981655
  • 财政年份:
    2015
  • 资助金额:
    $ 142.44万
  • 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
  • 批准号:
    9317459
  • 财政年份:
    2015
  • 资助金额:
    $ 142.44万
  • 项目类别:
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
  • 批准号:
    8792437
  • 财政年份:
    2014
  • 资助金额:
    $ 142.44万
  • 项目类别:
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
  • 批准号:
    9188625
  • 财政年份:
    2014
  • 资助金额:
    $ 142.44万
  • 项目类别:
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers
克服 CYP2D6 代谢不良者的曲马多耐药性
  • 批准号:
    8713969
  • 财政年份:
    2010
  • 资助金额:
    $ 142.44万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 142.44万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了